Effect of vitamin D in treatment of gestational diabetes

Effect of vitamin D supplementation on insulin resistance and inflammatory factors in women with gestational diabetes

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201305115623N7

Enrollment

Registered

2013-05-23

Start date

2013-05-15

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gestational diabetes mellitus. Diabetes mellitus in pregnancy, unspecified

Interventions

Intervention 1: Intervention group: Vitamin D3 capsule ( Zahravi Pharm Co, Iran), 50000 IU, every 3 weeks for 6 weeks orally. Intervention 2: Control group: Placebo capsule (Barij Essence Co, Iran), e

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Pregnant women aged 18-40 years Women diagnosed with Gestational Diabetes Mellitus 24-28 weeks' gestation

Exclusion criteria

Exclusion criteria: Premature preterm rupture of membrane Placenta abruption Preeclampsia Those who required commencing insulin therapy during intervention Those with hypothyroidism Urinary tract infection Smoking Those with kidney or liver diseases Those taking estrogen therapy

Design outcomes

Primary

Measure	Time frame
25-hydroxyvitamin D. Timepoint: Baseline and End-of-trial. Method of measurement: ELISA kit.;Newborn's lengt. Timepoint: Delivery time. Method of measurement: Tape.	—

Secondary

Measure	Time frame
Total antioxidant capacity. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;High-sensitivity C-reactive protein. Timepoint: Baseline and End-of-trial. Method of measurement: ELISA kit.;Insulin. Timepoint: Baseline and End-of-trial. Method of measurement: ELISA kit.;Insulin resistance. Timepoint: Baseline and End-of-trial. Method of measurement: Calculation using HOMA formula.;Triglycerides. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;Total cholesterol. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;HDL. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;Fasting plasma glucose. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;Ponderal index. Timepoint: Delivery time. Method of measurement: Calculation.;Newborn's head circumference. Timepoint: Delivery time. Method of measurement: Tape.;Polyhydramnios. Timepoint: End-of-trial. Method of measurement: Sonographic.;Calcium. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;Newborn's bilirubin. Timepoint: Delivery time. Method of measurement: Enzymatic kit.;Apgar score. Timepoint: Delivery time. Method of measurement: Clinical observation.;Newborns' hypoglycemia. Timepoint: After delivery. Method of measurement: Enzymatic kit.;Preterm delivery. Timepoint: After delivery. Method of measurement: Medical record.;Maternal pre-eclampsia. Timepoint: After delivery. Method of measurement: Medical record.;Maternal hospitalization. Timepoint: After delivery. Method of measurement: Medical record.;Newborns' hospitalization. Timepoint: After delivery. Method of measurement: Medical record.;LDL cholesterol. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.	—

Measure

Time frame

Total antioxidant capacity. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;High-sensitivity C-reactive protein. Timepoint: Baseline and End-of-trial. Method of measurement: ELISA kit.;Insulin. Timepoint: Baseline and End-of-trial. Method of measurement: ELISA kit.;Insulin resistance. Timepoint: Baseline and End-of-trial. Method of measurement: Calculation using HOMA formula.;Triglycerides. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;Total cholesterol. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;HDL. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;Fasting plasma glucose. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;Ponderal index. Timepoint: Delivery time. Method of measurement: Calculation.;Newborn's head circumference. Timepoint: Delivery time. Method of measurement: Tape.;Polyhydramnios. Timepoint: End-of-trial. Method of measurement: Sonographic.;Calcium. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;Newborn's bilirubin. Timepoint: Delivery time. Method of measurement: Enzymatic kit.;Apgar score. Timepoint: Delivery time. Method of measurement: Clinical observation.;Newborns' hypoglycemia. Timepoint: After delivery. Method of measurement: Enzymatic kit.;Preterm delivery. Timepoint: After delivery. Method of measurement: Medical record.;Maternal pre-eclampsia. Timepoint: After delivery. Method of measurement: Medical record.;Maternal hospitalization. Timepoint: After delivery. Method of measurement: Medical record.;Newborns' hospitalization. Timepoint: After delivery. Method of measurement: Medical record.;LDL cholesterol. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZatollah Asemi

Kashan University of Medical Sciences

asemi_r@yahoo.com+98 31 5562 0608

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 22, 2026